Baidu
map

Oncol Lett:在过敏性鼻炎中,线粒体ROS能够激活白介素-1β的表达

2018-09-05 AlexYang MedSci原创

过敏性鼻炎(AR)是鼻粘膜炎症最常见的起因。同样也是最常见的非传染性鼻炎,并且与免疫球蛋白E(lgE)介导的过敏原免疫响应有关。之前的研究表明了白介素-1β在过敏性哮喘的发展过程中具有病理作用。最近,有研究人员评估了是否IL-1β参与了AR的发病机理过程。研究总共包括了45名患有AR的患者,并且他们的外周血单个核细胞(PBMCs)中IL-1β表达增加;并且在AR患者中,单核细胞/巨噬细胞和PBMC

过敏性鼻炎(AR)是鼻粘膜炎症最常见的起因。同样也是最常见的非传染性鼻炎,并且与免疫球蛋白E(lgE)介导的过敏原免疫响应有关。之前的研究表明了白介素-1β在过敏性哮喘的发展过程中具有病理作用。

最近,有研究人员评估了是否IL-1β参与了AR的发病机理过程。研究总共包括了45名患有AR的患者,并且他们的外周血单个核细胞(PBMCs)中IL-1β表达增加;并且在AR患者中,单核细胞/巨噬细胞和PBMCs中IL-1β的合成需要线粒体活性氧(ROS)和NLRP3。另外,在AR患者中IL-1β和白介素-17(IL-17)的水平均增加,并且IL-1β和IL-17呈现正相关关系。

最后,研究人员指出,他们的研究表明了AR患者的线粒体ROS水平增高,从而上调IL-1β的表达,进一步影响IL-17的产生。因此,IL-1β在AR的发病机制中是有作用的。

原始出处:

Shi Q, Lei Z, Cheng G et al. Mitochondrial ROS activate interleukin-1β expression in allergic rhinitis. Oncol Lett. Sep 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047014, encodeId=b291204e014a0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 25 09:09:00 CST 2018, time=2018-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865533, encodeId=d58a1865533e2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Jul 20 15:09:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651335, encodeId=cf2b1651335b4, content=<a href='/topic/show?id=6eefe162275' target=_blank style='color:#2F92EE;'>#白介素-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71622, encryptionId=6eefe162275, topicName=白介素-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=859f24174096, createdName=zhangph, createdTime=Tue Aug 20 20:09:00 CST 2019, time=2019-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343430, encodeId=be3a343430e1, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Fri Sep 07 12:44:17 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364383, encodeId=1c48136438352, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Sep 07 12:09:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372117, encodeId=dced13e21177b, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Fri Sep 07 12:09:00 CST 2018, time=2018-09-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047014, encodeId=b291204e014a0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 25 09:09:00 CST 2018, time=2018-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865533, encodeId=d58a1865533e2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Jul 20 15:09:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651335, encodeId=cf2b1651335b4, content=<a href='/topic/show?id=6eefe162275' target=_blank style='color:#2F92EE;'>#白介素-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71622, encryptionId=6eefe162275, topicName=白介素-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=859f24174096, createdName=zhangph, createdTime=Tue Aug 20 20:09:00 CST 2019, time=2019-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343430, encodeId=be3a343430e1, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Fri Sep 07 12:44:17 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364383, encodeId=1c48136438352, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Sep 07 12:09:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372117, encodeId=dced13e21177b, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Fri Sep 07 12:09:00 CST 2018, time=2018-09-07, status=1, ipAttribution=)]
    2019-07-20 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=2047014, encodeId=b291204e014a0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 25 09:09:00 CST 2018, time=2018-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865533, encodeId=d58a1865533e2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Jul 20 15:09:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651335, encodeId=cf2b1651335b4, content=<a href='/topic/show?id=6eefe162275' target=_blank style='color:#2F92EE;'>#白介素-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71622, encryptionId=6eefe162275, topicName=白介素-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=859f24174096, createdName=zhangph, createdTime=Tue Aug 20 20:09:00 CST 2019, time=2019-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343430, encodeId=be3a343430e1, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Fri Sep 07 12:44:17 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364383, encodeId=1c48136438352, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Sep 07 12:09:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372117, encodeId=dced13e21177b, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Fri Sep 07 12:09:00 CST 2018, time=2018-09-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2047014, encodeId=b291204e014a0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 25 09:09:00 CST 2018, time=2018-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865533, encodeId=d58a1865533e2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Jul 20 15:09:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651335, encodeId=cf2b1651335b4, content=<a href='/topic/show?id=6eefe162275' target=_blank style='color:#2F92EE;'>#白介素-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71622, encryptionId=6eefe162275, topicName=白介素-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=859f24174096, createdName=zhangph, createdTime=Tue Aug 20 20:09:00 CST 2019, time=2019-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343430, encodeId=be3a343430e1, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Fri Sep 07 12:44:17 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364383, encodeId=1c48136438352, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Sep 07 12:09:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372117, encodeId=dced13e21177b, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Fri Sep 07 12:09:00 CST 2018, time=2018-09-07, status=1, ipAttribution=)]
    2018-09-07 lietome24

    好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2047014, encodeId=b291204e014a0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 25 09:09:00 CST 2018, time=2018-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865533, encodeId=d58a1865533e2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Jul 20 15:09:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651335, encodeId=cf2b1651335b4, content=<a href='/topic/show?id=6eefe162275' target=_blank style='color:#2F92EE;'>#白介素-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71622, encryptionId=6eefe162275, topicName=白介素-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=859f24174096, createdName=zhangph, createdTime=Tue Aug 20 20:09:00 CST 2019, time=2019-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343430, encodeId=be3a343430e1, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Fri Sep 07 12:44:17 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364383, encodeId=1c48136438352, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Sep 07 12:09:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372117, encodeId=dced13e21177b, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Fri Sep 07 12:09:00 CST 2018, time=2018-09-07, status=1, ipAttribution=)]
    2018-09-07 lsndxfj
  6. [GetPortalCommentsPageByObjectIdResponse(id=2047014, encodeId=b291204e014a0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 25 09:09:00 CST 2018, time=2018-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865533, encodeId=d58a1865533e2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Jul 20 15:09:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651335, encodeId=cf2b1651335b4, content=<a href='/topic/show?id=6eefe162275' target=_blank style='color:#2F92EE;'>#白介素-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71622, encryptionId=6eefe162275, topicName=白介素-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=859f24174096, createdName=zhangph, createdTime=Tue Aug 20 20:09:00 CST 2019, time=2019-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343430, encodeId=be3a343430e1, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Fri Sep 07 12:44:17 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364383, encodeId=1c48136438352, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Sep 07 12:09:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372117, encodeId=dced13e21177b, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Fri Sep 07 12:09:00 CST 2018, time=2018-09-07, status=1, ipAttribution=)]

相关资讯

Ear Nose Throat J:在季节过敏性鼻炎中,孟鲁司特作为一种预防性治疗效果研究

在季节过敏性鼻炎中,能够支持花粉季节开始之前进行预防性治疗的证据仍旧很少。最近,有研究人员进行了一项研究,调查了孟鲁司特对季节过敏性鼻炎预防治疗的效果,并且评估了对下呼吸道炎症情况的影响。研究群体包括了57名成年人,并被随机分配到了预防性治疗组和对照组。预防性治疗组包括了31名患者(10名男性和21名女性,年龄在18到54岁之间(平均年龄为36.9岁))。预防性治疗组接受孟鲁司特治疗,在柏树花粉季

Clin Transl Allergy:重度过敏性鼻炎能够影响睡眠和焦虑

过敏性鼻炎(AR)是一种高度流行的疾病,并且能够产生高的社会和医疗费用,并且对生活质量和睡眠质量也有明显的影响。过敏性鼻炎同样与一些心理障碍有关,比如焦虑或者抑郁。最近,有研究人员评估并比较了患有永久性AR患者与季节性AR患者在焦虑、抑郁、睡眠质量和生活改变方面情况。研究包括了670名西班牙成年人,他们患有永久性AR或者季节性AR,并根据他们的季节性症状分为永久性和季节性2个组。研究人员利用相关的

Nat Genet:全基因组关联和HLA精细定位研究鉴定过敏性鼻炎的风险位点和遗传途径

过敏性鼻炎过敏症状中最为常见的临床表现,在全世界范围内影响着4亿的人口,并且在西方国家中发生率正在增加。最近,有研究人员为了阐释过敏性鼻炎的遗传结构和理解潜在的疾病机制,在具有欧洲血统的59762个过敏性鼻炎案例和152358个对照中进行了元分析,并总共鉴定了41个过敏性鼻炎的风险位点,包括了20个之前与过敏性鼻炎不相关的位点,这些位点在一个重复的试验(60720个案例和618527个对照)中得到

Mol Immunol:在过敏性鼻炎患者中,组织缺氧能够打乱芳香烃受体信号和Th17响应

组织缺氧是过敏性鼻炎(AR)的关键特性,然而,在AR中组织缺氧产生的影响还没有完全的认识。最近,有研究人员通过调查组织缺氧影响的信号通路对Th17分化的作用,探究了组织缺氧对Th17响应的影响。研究包括了23名AR患者和15名健康的对照。在常氧和缺氧条件下,研究人员测量了HIF-1α, AhR, CYP1A1和CYP1B1的表达情况以及Th17细胞在CD4+T细胞中的表现情况。研究发现,与健康对照

J Int Med Res:中草药治疗儿童过敏性鼻炎效果研究

最近,有研究人员系统性的评估了中草药(CHM)治疗儿童过敏性鼻炎的效果。研究人员在MEDLINE (PubMed)、Embase、Cochrane Central Register of Controlled Trials、 Chinese National Knowledge Infrastructure、the Cqvip Database、和the Wanfang Database等数据库中

Allergy:SQ屋尘螨舌下免疫治疗药片疗效和安全性研究

SQ屋尘螨(HDM)舌下免疫治疗(SLIT)药片治疗在治疗年龄不小于12岁患者的呼吸道过敏性疾病中是有效的。最近,有研究人员调查了上述治疗方法在日本5-17岁患有中度到重度HMD过敏性鼻炎(AR)患者中的效果和安全性。研究是一个随机、双盲和安慰剂对照实验,458名日本儿童随机分配到治疗组和安慰剂对照组,进行为期1年的治疗和调查。研究的主要结果是治疗结束前8周的总的组合鼻炎得分(TCRS),包括AR

Baidu
map
Baidu
map
Baidu
map